Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell and gene therapies, has announced its upcoming annual shareholders general meeting. The meeting is scheduled for June 26, 2025, at 2:30 p.m. CET and will be held at the Biopark auditorium in Paris, France. Shareholders can access detailed information about the meeting agenda and participation modalities through the company's website.
Cellectis (NASDAQ: CLLS), un'azienda biotecnologica in fase clinica specializzata in editing genetico e terapie cellulari e geniche, ha annunciato la prossima assemblea annuale degli azionisti. L'incontro è previsto per il 26 giugno 2025, alle 14:30 CET e si terrà nell'auditorium Biopark a Parigi, Francia. Gli azionisti possono trovare informazioni dettagliate sull'ordine del giorno e sulle modalità di partecipazione sul sito web dell'azienda.
Cellectis (NASDAQ: CLLS), una empresa biotecnológica en fase clínica centrada en la edición genética y terapias celulares y génicas, ha anunciado su próxima junta anual de accionistas. La reunión está programada para el 26 de junio de 2025 a las 14:30 CET y se llevará a cabo en el auditorio Biopark en París, Francia. Los accionistas pueden acceder a información detallada sobre la agenda y las modalidades de participación a través del sitio web de la empresa.
Cellectis (NASDAQ: CLLS)는 유전자 편집 및 세포 및 유전자 치료에 중점을 둔 임상 단계의 생명공학 회사로, 곧 개최될 연례 주주총회를 발표했습니다. 총회는 2025년 6월 26일 오후 2시 30분 CET에 프랑스 파리의 Biopark 강당에서 열릴 예정입니다. 주주들은 회사 웹사이트를 통해 회의 안건과 참여 방법에 대한 자세한 정보를 확인할 수 있습니다.
Cellectis (NASDAQ : CLLS), une société de biotechnologie en phase clinique spécialisée dans l'édition génétique ainsi que les thérapies cellulaires et géniques, a annoncé sa prochaine assemblée générale annuelle des actionnaires. Cette réunion est prévue pour le 26 juin 2025 à 14h30 CET et se tiendra dans l'auditorium du Biopark à Paris, France. Les actionnaires peuvent consulter des informations détaillées sur l'ordre du jour et les modalités de participation sur le site web de la société.
Cellectis (NASDAQ: CLLS), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Gen-Editing sowie Zell- und Gentherapien, hat seine bevorstehende jährliche Hauptversammlung angekündigt. Die Versammlung ist für den 26. Juni 2025 um 14:30 Uhr MEZ geplant und findet im Biopark-Auditorium in Paris, Frankreich, statt. Aktionäre können ausführliche Informationen zur Tagesordnung und den Teilnahmebedingungen auf der Unternehmenswebsite einsehen.
- None.
- None.
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
The notice convening the annual general meeting stating the detailed agenda and modalities of participation in the meeting and the report of the board of directors to the shareholders meeting are available on the Cellectis website: https://www.cellectis.com/en/investors/general-meetings/
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
When and where is Cellectis (CLLS) holding its 2025 annual shareholders meeting?
How can shareholders access information about Cellectis' 2025 annual meeting?
What is Cellectis (CLLS) main business focus?
On which stock exchanges is Cellectis traded?
